![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() By Robin MILLARD Geneva (AFP) June 1, 2021
The World Health Organization on Tuesday approved the Sinovac Covid-19 vaccine for emergency use -- the second Chinese jab to receive the WHO's green light. The UN health agency signed off on the Beijing-based firm Sinovac's two-dose vaccine CoronaVac, which is already being deployed in several countries around the world. "I'm happy to announce that the Sinovac-CoronaVac vaccine has been given WHO emergency use listing after being found to be safe, effective, and quality-assured," WHO chief Tedros Adhanom Ghebreyesus told a press conference. "The easy storage requirements of CoronaVac make it very suitable for low-resource settings," he added. "It's now crucial to get these life-saving tools to the people that need them quickly." The WHO said the emergency use listing (EUL) gives countries, funders, procuring agencies and communities assurance that the vaccine has met international standards. Last month Sinopharm became the first Chinese vaccine to be approved by the WHO. The organisation has also given EUL status to vaccines being made by Pfizer/BioNTech, Moderna, Johnson & Johnson, and the AstraZeneca jab being produced in India, South Korea and the EU, which it counts separately. WHO's listing paves the way for countries worldwide to approve and import a vaccine for distribution quickly, especially those states without an international-standard regulator of their own. It also opens the door for the jabs to enter the Covax global vaccine-sharing facility, which aims to provide equitable access to doses around the world, particularly in poorer countries. Currently only AstraZeneca and some Pfizer jabs are flowing through the scheme. "The world desperately needs multiple Covid-19 vaccines to address the huge access inequity across the globe," said Mariangela Simao, the WHO's assistant director general for access to health products. "We urge manufacturers to participate in the Covax facility, share their know-how and data and contribute to bringing the pandemic under control." - Efficacy rate - "WHO recommends the vaccine for use in adults 18 years and older, in a two-dose schedule with a spacing of two to four weeks," the agency said in a statement. "Vaccine efficacy results showed that the vaccine prevented symptomatic disease in 51 percent of those vaccinated and prevented severe Covid-19 and hospitalisation in 100 percent of the studied population." The Sinovac vaccine contains an inactivated form of coronavirus that cannot cause the disease. It also has a substance that helps strengthen the immune response to the vaccine. When given the shot, the immune system identifies the inactivated virus as foreign and makes antibodies against it, which will then recognise the active virus and defend the body against it. Few people aged over 60 took part in the clinical trial of Sinovac's jab. However, the WHO said there should be no upper age limit on the vaccine as there is "no reason to believe it has a different safety profile" in older generations. The Sinovac jab is already in use in 22 territories around the world, according to an AFP count. Apart from China, the countries using Sinovac include Chile, Brazil, Indonesia, Mexico, Thailand and Turkey. Chen Xu, China's ambassador in Geneva, said CoronaVac's EUL status expanded the number of global tools to fight the pandemic. "China will continue to work with the international community to promote the accessibility and affordability of Covid-19 vaccines especially in (the) developing world," he said in a tweet. rjm/nl/dl
![]() ![]() China rails at Biden intelligence probe into virus origins Beijing (AFP) May 27, 2021 China hit out at the "dark history" of the US intelligence community Thursday, after President Joe Biden ordered a probe into the Covid-19 origins which threatens to set the course for relations between world's top economies. Washington is reviewing its diplomatic position with China on issues spanning trade, technological supremacy and rights, while it steps up efforts to hook Western democracies into a united diplomatic front against perceived Chinese aggression. The countries' trade envoys ha ... read more
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |